MyelinWatch EL
← Studies & programmes
Myelin repairPreparing for a first study in peopleResearch, not an established treatment

Lucid-21-302: a planned Phase 2 test of PAD2 inhibition

Published by MyelinWatch:

Organisation
Quantum BioPharma / Lucid Psycheceuticals
Regulator
US Food and Drug Administration · United States

Lucid-MS / Lucid-21-302 · Researchers plan to test whether Lucid-21-302, which blocks PAD2, can be studied safely and may help in progressive MS.

What is the approach?

Lucid-21-302 is designed to inhibit PAD2, an enzyme that can citrullinate proteins in myelin. The proposed idea is to reduce excessive citrullination and protect myelin from damage; that protective effect comes from experimental work and has not been shown to remyelinate people with MS.

Approach source: Quantum BioPharma — SEC-filed development announcement ↗ ACTRIMS Forum 2023 — Lucid-21-302 experimental abstract ↗

What is being studied

Researchers plan to test whether Lucid-21-302, which blocks PAD2, can be studied safely and may help in progressive MS.

Research stage

Preparing for a first study in people

A human study is planned; no current participation route is listed.

What we know so far

The FDA has allowed development to proceed, but no public Phase 2 trial registration or participating site is listed here. No patient benefit is established.

What this means for patients today

This permission step is not evidence that the approach works or a current way to join a trial.

Treatment or approach
Lucid-21-302, a drug that blocks PAD2 • progressive MS
How it is intended to work
Blocks the PAD2 enzyme, which may be involved in myelin damage
Where the study is running
No centres have been announced • no option to participate in Greece at present
Source: Quantum BioPharma — official company statement filed with the US SEC ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first

  1. Planned Phase 2 trialResearch event/source date:

    Lucid-MS: study start-up agreement for a planned Phase 2 trial

    Quantum BioPharma says it signed a Study Start-Up Agreement with Thermo Fisher Scientific's PPD clinical research business to prepare a planned Phase 2 trial of Lucid-21-302 (Lucid-MS) in people with progressive forms of multiple sclerosis (MS). The planned trial would compare Lucid-MS with placebo and assess efficacy, safety and tolerability.

    Source: Quantum BioPharma — company announcement filed with the US Securities and Exchange Commission ↗